Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC
Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
Interview with Douglas B. Johnson, MD, author of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
Anti–PD-1 Immunotherapy in Microsatellite-Stable Tumors With 10 or More Mutations per Megabase
Interview with Luc GT Morris, MD MSc, author of Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase
Virtual Care Across a Tertiary Cancer Center During COVID-19
Interview with Alejandro Berlin, MD, MSc, author of Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19
Osteonecrosis of the Jaw in Patients Receiving Zoledronic Acid for Bone Metastases
Interview with Catherine Van Poznak, MD, author of Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer
Discontinuation of Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Interview with Ehab Atallah, MD, author of Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial
Love these JAMA podcasts, I work in oncology and this helps keep me up to date.